New role enhances company’s strong leadership team and solidifies commitment to ongoing clinical innovation DOYLESTOWN, Pa. , May 02, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision
Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and effective treatment for Cyclin E-overexpressing cancers IND for APR-1051 has been cleared; details on planned Phase 1 first in human trial (ACESOT-1051) presented
First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation and potentially generate human efficacy data in H2 2024 U.S. FDA cleared IND for APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor; Company plans to initiate Phase 1 ACESOT-1051
Financing led by Sphera Healthcare with participation from new and existing healthcare-focused institutional investors $16.0 million in upfront gross proceeds with the potential to receive up to an additional $18.0 million in potential warrant exercise proceeds for an aggregate of up to $34.0
Company plans to initiate Phase 1 ACESOT-1051 ( A Multi- C enter E valuation of WEE1 Inhibitor in Patients with Advanced So lid T umors, APR- 1051 ) clinical trial evaluating , highly selective, oral WEE1 inhibitor, for monotherapy treatment of Cyclin E overexpressing cancers including breast and
Four Poster Presentations, Including Posters on ATRN-119 (novel macrocyclic ATR inhibitor) and APR-1051 (next generation WEE1 kinase inhibitor) DOYLESTOWN, Pa. , March 05, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a clinical-stage
DOYLESTOWN, Pa. , Feb. 06, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has submitted an Investigational New Drug (IND)
DOYLESTOWN, Pa. , Jan. 30, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Dr. Oren Gilad , President and CEO, will deliver a
DOYLESTOWN, Pa. , Jan. 04, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today provided a corporate update highlighting recent developments and
DOYLESTOWN, Pa. , Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the three and nine months ended